advanced search
2025_Oct_Sanner_Leaderboard

PULMONARY

REVIEWING CURRENT THINKING ON THE <i>IN VIVO</i> BEHAVIOUR OF PARTICLES IN THE EXTRA-FINE REGION
PULMONARY
Dr David Lewis
REVIEWING CURRENT THINKING ON THE IN VIVO BEHAVIOUR OF PARTICLES IN THE EXTRA-FINE REGION
David Lewis reports the latest research on the changing view of the behaviour of particles in the extra-fine region and their potential for enhancing inhaled drug therapies.
IMPROVING DRUG STABILITY & DRUG DELIVERY BY MODIFICATION OF MDI CANISTER SURFACES
PULMONARY
Richard Turner
H&T Presspart
IMPROVING DRUG STABILITY & DRUG DELIVERY BY MODIFICATION OF MDI CANISTER SURFACES
Richard Turner explains how, in recent years, a number of surface coatings have been developed that can be applied to MDIs canisters and valve components, to protect the contents from deposition and degradation.
A NEW, ADVANCED HIGH-THROUGHPUT SYSTEM FOR AUTOMATED INHALER TESTING
PULMONARY
Adam Smith
Copley Scientific
A NEW, ADVANCED HIGH-THROUGHPUT SYSTEM FOR AUTOMATED INHALER TESTING
Adam Smith introduces DecaVertus, describing its single inhaler predecessor the Vertus, and how the DecaVertus design evolved using the Vertus technology.
INVESTIGATING THE DE-AGGLOMERATION PROFILES OF DPI FORMULATIONS
PULMONARY
Dr Paul Kippax
Malvern Panalytical
INVESTIGATING THE DE-AGGLOMERATION PROFILES OF DPI FORMULATIONS
Paul Kippax from Malvern Instruments, Srinivas Ravindra Babu Behara, David Morton, Ian Larson and Peter Stewart from Monash University describe the use of laser diffraction to analyse dry powder behaviour.
MDI PROPELLANTS – IS THE POPULARITY OF HFA 227EA SET TO GROW?
PULMONARY
Dr Timothy Noakes
MDI PROPELLANTS – IS THE POPULARITY OF HFA 227EA SET TO GROW?
Tim Noakes predicts a rise in demand for HFA 227ea – a less common MDI propellant than the better-known HFA 134a.
IMPROVING THE REALISM AND RELEVANCE OF MOUTH-THROAT MODELS FOR INHALED PRODUCT TESTING
PULMONARY
Mark Copley
Copley Scientific
IMPROVING THE REALISM AND RELEVANCE OF MOUTH-THROAT MODELS FOR INHALED PRODUCT TESTING
Mark Copley provides some background on mouth-throat models for OIP testing.
THE ADVANTAGES OF DESIGNING HIGH-RESISTANCE SWIRL CHAMBERS
PULMONARY
David Harris
Team Consulting
THE ADVANTAGES OF DESIGNING HIGH-RESISTANCE SWIRL CHAMBERS
David Harris taps into a powerful combination of detailed anatomical and functional understanding of the human respiratory system, pulmonary drug delivery technology and formulation expertise.
PULMONARY DELIVERY OF ANTIMICROBIAL PEPTIDES
PULMONARY
Dr Anna Fureby
PULMONARY DELIVERY OF ANTIMICROBIAL PEPTIDES
Anna Fureby, Ulla Elofsson and Per Gerde discuss the serious problem of antibiotic resistance and the potential role of antimicrobial peptides in the treatment of resistant bacterial strains.
EXPERTISE IN DEVELOPMENT, MANUFACTURING & COMMERCIALISATION
PULMONARY
EXPERTISE IN DEVELOPMENT, MANUFACTURING & COMMERCIALISATION
3M Drug Delivery Systems reports on how it has achieved significant successes thanks to its deep expertise in the field of MDIs.
PROTECTING INHALATION DRUG DELIVERY DEVICES WITH PARYLENE CONFORMAL COATINGS
PULMONARY
Richard Molin
PROTECTING INHALATION DRUG DELIVERY DEVICES WITH PARYLENE CONFORMAL COATINGS
Dick Molin describes applications of Parylene coatings as protective barrier coatings in inhalable drug delivery devices, and the detailed characteristics of Parylene which make it particularly suited to these applications.
QUALITY BY DESIGN IN INHALATION PRODUCT DEVELOPMENT
PULMONARY
Dr Carole Evans
Catalent Pharma Solutions
QUALITY BY DESIGN IN INHALATION PRODUCT DEVELOPMENT
Carole Evans and Lei Mao explore the application and principles of quality by design in the development, manufacture and commercialisation of inhaled pharmaceutical products.
DESIGN OF COMPOSITE PARTICLES VIA SPRAY DRYING FOR DPI FORMULATIONS
PULMONARY
Dr Eunice Costa
Hovione
DESIGN OF COMPOSITE PARTICLES VIA SPRAY DRYING FOR DPI FORMULATIONS
Eunice Costa, Filipe Neves and Cláudia Moura describe how composite formulations - API embedded in an excipient matrix - overcome the challenges in inhalation powder development.
EFFECTS OF STATIC ON PLASTICS USED IN DRUG DELIVERY DEVICES
PULMONARY
Dr Joel Bell
EFFECTS OF STATIC ON PLASTICS USED IN DRUG DELIVERY DEVICES
Drug delivery in dry-powder and aerosol inhalers can be hindered by static attraction of the drug substance to plastics used in the drug flow path. JoelBell and Josh Blackmore report a series of projects to characterise this interaction.
THE SIGNIFICANCE OF INHALER TECHNIQUE & HOW TO IMPROVE IT
EXPERT VIEW
Prof David Price
THE SIGNIFICANCE OF INHALER TECHNIQUE & HOW TO IMPROVE IT
Professor David Price describes a significant and long-standing unmet need for inhaler technique to be improved in patients with asthma and COPD, and sets forth strategies to achieve the sorely needed improvements.
FORMULATION METHODS & SIZE REDUCTION FOR INHALERS
PULMONARY
Bert Dekens
FORMULATION METHODS & SIZE REDUCTION FOR INHALERS
Bert Dekens highlights the importance of achieving the correct particle sizes, both for the API and the carrier in formulations for inhalation, and describes some of the available equipment most suited to specific tasks.
THE eFLOW “CLOSED SYSTEM”
PULMONARY
Thomas Gallem
PARI
THE eFLOW “CLOSED SYSTEM”
Thomas Gallem describes the design and development stages, including the incorporation of human-factors engineering and optimisation for elderly patients, of the company’s eFlow CS nebuliser, which uses a proprietary single-dose drug ampoule as an integral part of the nebuliser handset.
GENERIC PMDI PRODUCT DEVELOPMENT FOR THE US: KEY CONSIDERATIONS
PULMONARY
Badre Hammond
Next Breath
GENERIC PMDI PRODUCT DEVELOPMENT FOR THE US: KEY CONSIDERATIONS
Badre Hammond highlights key considerations and addresses strategies that are believed to reduce risk and ultimately speed up the process for getting a generic pMDI product to the US market.
ARTIFICIAL NEURAL NETWORKS & TISSUE MODELS
PULMONARY
Prof Marc Brown
MedPharm
ARTIFICIAL NEURAL NETWORKS & TISSUE MODELS
Marc Brown, Jo Muddle and Professor Clive Page describe the use of artificial neural networks and novel tissue models as methods for formulation candidate screening, selection and characterisation and, in generic product development, for bioequivalence testing.
SCALE-UP & QBD APPROACHES FOR SPRAY-DRIED INHALATION FORMULATIONS
PULMONARY
Dr Eunice Costa
Hovione
SCALE-UP & QBD APPROACHES FOR SPRAY-DRIED INHALATION FORMULATIONS
Eunice Costa, Filipe Neves, Gonçalo Andrade and Conrad Winters describe the strong position of inhalable products in preclinical and clinical pipelines and make the case for formulation-based approaches to enable and enhance pulmonary product development. Spray-drying technology in particular is highlighted as a highly favourable, scalable manufacturing technique for inhalable composite particles.
RESPIRATORY DRUG DELIVERY (RDD) 2014
CONFERENCE REVIEW
RESPIRATORY DRUG DELIVERY (RDD) 2014
Respiratory Drug Delivery® celebrated its 25th Anniversary at the El Conquistador Resort in Fajardo, Puerto Rico, from May 4 to May 8, 2014.
Top